Abstract
Non-small cell lung cancer (NSCLC) is a genetically inhomogeneous disease, and a number of genetic aberrations have been detected, especially in adenocarcinomas, which predict the effectiveness of targeted therapy. These include RET gene fusions, which are present in about 1-2% of NSCLC and predict the effectiveness of RET inhibitor therapy.
In this indication, in November 2021 EMA has approved pralsetinib, an oral tyrosine kinase inhibitor that selectively and strongly targets oncogenic RET fusions and mutations.